OverviewSuggest Edit

Adynxx is a biopharmaceutical company focused on bringing to market disease-modifying products for the treatment of pain and inflammation. It works to discover and develop transcription factor decoys to modify the course of pain, to collaborate with discovery partners, and to identify in-licensing opportunities with transformative therapeutic profiles to build a pipeline in pain and inflammation.

TypePublic
Founded2007
HQSan Francisco, US
Websiteadynxx.com

Latest Updates

Revenue (FY, 2018)$2.2 M(-88%)
Share Price (Oct 2020)$0.1
Cybersecurity ratingAMore

Key People/Management at Adynxx

Rick Orr

Rick Orr

President and Chief Executive Officer
Julien Mamet

Julien Mamet

Founder and Chief Scientific Officer
Donald C. Manning

Donald C. Manning

Chief Medical Officer
Kimberley Hebert

Kimberley Hebert

Senior Director, Clinical Operations
Eckard Weber

Eckard Weber

Director
Dennis Podlesak

Dennis Podlesak

Chairman
Show more

Adynxx Office Locations

Adynxx has an office in San Francisco
San Francisco, US (HQ)
100 Pine St, San Francisco
Show all (1)

Adynxx Financials and Metrics

Adynxx Revenue

Embed Graph
View revenue for all periods
Adynxx's revenue was reported to be $2.22 m in FY, 2018
USD

Net income (Q3, 2019)

(1.9m)

EBIT (Q3, 2019)

(1.7m)

Market capitalization (19-Oct-2020)

580.8k

Closing stock price (19-Oct-2020)

0.1

Cash (30-Sept-2019)

331.0k

EV

9.7m
Adynxx's current market capitalization is $580.8 k.
USDQ2, 2011

Financial Leverage

1 x
Show all financial metrics

Adynxx Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Adynxx Online and Social Media Presence

Embed Graph

Adynxx News and Updates

Adynxx Reports Third Quarter 2019 Financial Results

SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced financial…

Adynxx Reports Second Quarter 2019 Financial Results

SAN FRANCISCO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced financial…

Adynxx Stock to Move to OTC Market Following Receipt of Nasdaq Delisting Notice

Company on Track with All Business Operations and Clinical Development Plans for Brivoligide While Pursuing Options to Comply with Nasdaq’s Initial Listing Requirements Company on Track with All Business Operations and Clinical Development Plans for Brivoligide While Pursuing Options to Comply with …

Adynxx Announces Payment Date of Special Cash Dividend Previously Announced by Alliqua BioMedical

Adynxx announces May 29, 2019 as payment date of previously announced special cash dividend of $1.05 per share to former Alliqua shareholders

Adynxx, Inc. Receives Nasdaq Notice of Delisting or Failure to Satisfy an Initial Listing Rule or Standard

SAN FRANCISCO, May 09, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq:ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced that it recei…

Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors

– Newly Nasdaq-traded Adynxx (ADYX) focused on development of novel, non-opioid therapeutics for the treatment of pain and inflammatory diseases – – Newly Nasdaq-traded Adynxx (ADYX) focused on development of novel, non-opioid therapeutics for the treatment of pain and inflammatory diseases –
Show more

Adynxx Frequently Asked Questions

  • When was Adynxx founded?

    Adynxx was founded in 2007.

  • Who are Adynxx key executives?

    Adynxx's key executives are Rick Orr, Julien Mamet and Donald C. Manning.

  • What is Adynxx revenue?

    Latest Adynxx annual revenue is $2.2 m.

  • Who are Adynxx competitors?

    Competitors of Adynxx include Immune Therapeutics, Celyad and aTyr Pharma.

  • Where is Adynxx headquarters?

    Adynxx headquarters is located at 100 Pine St, San Francisco, San Francisco.

  • Where are Adynxx offices?

    Adynxx has an office in San Francisco.

  • How many offices does Adynxx have?

    Adynxx has 1 office.